← Human Trials & Peer-Reviewed Studies
Impact of recombinant human growth hormone treatment on psychological profiles in hypopituitary patients with adult-onset growth hormone deficiency.
Plain-language guide to PMID 9502182 (1998): randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 25 patients.
Key Facts
- PMID
- 9502182
- Journal
- European journal of clinical investigation
- Year
- 1998
- Study type
- Randomized Controlled Trial
- Authors
- Giusti M et al. (8 authors)
- DOI
- 10.1046/j.1365-2362.1998.00239.x
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.
The researchers examined the effect of growth hormone (GH) administration on the psychological capacity and sense of well-being in 25 patients with adult-onset GH-deficiency (GHD).
Who Took Part
The study group was 25 patients.
By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.
How the Study Was Run
The researchers set it up as a randomized and placebo-controlled study.
Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Some patients received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.
Quality of life was assessed by using the Italian version of the self-rating Kellner Symptom Questionnaire (KSQ) and the Hamilton Depression Scale (HDS).
What Was Measured
Topics PubMed links to this paper include Depressive Disorder, Human Growth Hormone, Hypopituitarism, Insulin-Like Growth Factor I, Neuropsychological Tests and Personality Inventory.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 25 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 1998 (European journal of clinical investigation), a journal based in England.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.